Hill-Rom Holdings Inc (NYSE:HRC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “Over the last three months, Hill-Rom has been underperforming the broader industry. Moreover, it exited the last reported quarter on a mixed note with earnings ahead of estimates but revenues missing the same. Also, decrease in Patient Support Systems revenues was disappointing. Moreover, a decline in reported gross margin was dampening. Also, lowered full year guidance suggests dull prospects ahead. On a positive note, Hill-Rom saw a solid year-over-year increase in revenues on strong international growth. Hill-Rom currently aims to gain traction in the untapped international market on successful execution. The company is focusing on product innovation through research and development. Also, its launches slated for the fourth quarter are pumping up investors’ confidence. With regard to this, the commercial launch of its Centrella Med-Surg platform is worth a mention.”

A number of other research firms have also weighed in on HRC. BidaskClub lowered Hill-Rom Holdings from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Needham & Company LLC reduced their price objective on Hill-Rom Holdings from $95.00 to $93.00 and set a “buy” rating for the company in a research note on Friday, July 28th. Barclays PLC lifted their price objective on Hill-Rom Holdings from $80.00 to $86.00 and gave the company an “overweight” rating in a research note on Friday, June 9th. Morgan Stanley lifted their price objective on Hill-Rom Holdings from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, June 30th. Finally, Cantor Fitzgerald initiated coverage on Hill-Rom Holdings in a research note on Thursday, June 29th. They set a “neutral” rating and a $86.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Hill-Rom Holdings currently has a consensus rating of “Buy” and a consensus price target of $88.17.

Hill-Rom Holdings (HRC) traded down 0.258% during mid-day trading on Monday, reaching $75.405. The company had a trading volume of 284,976 shares. The firm has a market capitalization of $4.97 billion, a PE ratio of 43.942 and a beta of 1.21. The stock’s 50-day moving average price is $75.30 and its 200 day moving average price is $75.12. Hill-Rom Holdings has a 52 week low of $50.50 and a 52 week high of $84.65.

Hill-Rom Holdings (NYSE:HRC) last issued its earnings results on Friday, July 28th. The medical technology company reported $0.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.90 by $0.01. The company had revenue of $689.10 million during the quarter, compared to analyst estimates of $695.50 million. Hill-Rom Holdings had a return on equity of 19.99% and a net margin of 4.27%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the business posted $0.81 EPS. On average, equities research analysts predict that Hill-Rom Holdings will post $3.82 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/18/hill-rom-holdings-inc-hrc-upgraded-to-hold-at-zacks-investment-research.html.

In other Hill-Rom Holdings news, SVP Andreas G. Frank sold 3,940 shares of Hill-Rom Holdings stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $77.84, for a total transaction of $306,689.60. Following the completion of the transaction, the senior vice president now owns 16,701 shares in the company, valued at approximately $1,300,005.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Andreas G. Frank sold 6,870 shares of Hill-Rom Holdings stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $77.48, for a total value of $532,287.60. Following the transaction, the senior vice president now owns 16,701 shares of the company’s stock, valued at approximately $1,293,993.48. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Lord Abbett & CO. LLC increased its stake in shares of Hill-Rom Holdings by 535.6% in the 2nd quarter. Lord Abbett & CO. LLC now owns 543,398 shares of the medical technology company’s stock valued at $43,260,000 after purchasing an additional 457,898 shares in the last quarter. Koch Industries Inc. purchased a new position in shares of Hill-Rom Holdings in the 2nd quarter valued at about $1,007,000. Ameritas Investment Partners Inc. increased its stake in shares of Hill-Rom Holdings by 2.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 17,910 shares of the medical technology company’s stock valued at $1,426,000 after purchasing an additional 378 shares in the last quarter. Nomura Holdings Inc. purchased a new position in shares of Hill-Rom Holdings in the 2nd quarter valued at about $332,000. Finally, 361 Capital LLC increased its stake in shares of Hill-Rom Holdings by 68.3% in the 2nd quarter. 361 Capital LLC now owns 22,886 shares of the medical technology company’s stock valued at $1,822,000 after purchasing an additional 9,287 shares in the last quarter. Hedge funds and other institutional investors own 82.31% of the company’s stock.

About Hill-Rom Holdings

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom Holdings (NYSE:HRC)

Receive News & Stock Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related stocks with our FREE daily email newsletter.